Vaccination Rates Are Stagnating
In 2024, 14.3 million children worldwide were classified as 'zero-dose', meaning they had not received a single vaccine.
This number has barely changed over the past two years (14.5 million in 2022) and remains higher than the 12.8 million recorded in 2019, before the Covid-19 pandemic disrupted health services.
More than half of these unvaccinated children live across around 30 countries currently affected by fragility, conflict or other vulnerabilities.
As Statista's Anna Fleck shows in the following chart, the percentage of children who received three doses of the DTP vaccine (which protects against diphtheria, tetanus, and pertussis) stood at 85 percent in 2024. This is slightly below from the 86 percent reached between 2016 and 2019.
You will find more infographics at Statista
Vaccination rates for other diseases have also stagnated: polio coverage remained at 84 percent in 2024 (down from 86 percent between 2017 and 2019), and tuberculosis vaccination held steady at 88 percent (compared to a peak of 90 percent in 2017 and 2018).
As for measles, global coverage improved significantly between 2004 and 2016 but has since slowed.
In 2024, the global measles vaccination rate reached 76 percent, up from 71 percent in 2019, yet still well below the 95 percent threshold needed to effectively prevent outbreaks.
According to the WHO, 60 countries experienced 'major or disruptive' measles outbreaks in 2024 – nearly double the number recorded in 2022.
The primary reason for low vaccination coverage remains limited access to vaccines in certain regions.
However, the WHO also highlights the growing threat posed by misinformation about science and vaccines.
Also read: US Government Drops Charges Against Doctor Who Issued Fake COVID Vaccination Cards
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
3 days ago
- Daily Tribune
WHO Issues Urgent Warning Over Re-Emerging Mosquito-Borne Virus
The World Health Organization (WHO) has sounded the alarm over the re-emergence of the mosquito-borne Chikungunya virus, warning that the world may be facing a repeat of a major outbreak that occurred two decades ago. At a press conference in Geneva on Tuesday, Dr. Diana Alvarez, a medical officer at WHO, revealed that an estimated 5.6 billion people in 119 countries currently live in areas at risk of Chikungunya infection. The virus, which is transmitted through mosquito bites, can cause high fever, joint pain, and even long-term disability. 'We are watching history repeat itself,' Dr. Alvarez said, referring to the 2004–2005 outbreak, which infected nearly half a million people—mostly on small islands—before spreading globally. The latest wave began in early 2025 in the same Indian Ocean islands previously affected, including La Réunion, Mayotte, and Mauritius. Alvarez noted that about one-third of La Réunion's population has already been infected. The virus is now spreading in Madagascar, Somalia, and Kenya, with growing concern over its spread in Southeast Asia, particularly India. Even more troubling is the recent appearance of Chikungunya cases in parts of Europe, indicating the virus is reaching new regions. The word 'Chikungunya' comes from a local language and means 'to bend over' or 'to walk hunched,' due to the intense joint and muscle pain caused by the illness. What are the symptoms? According to the Mayo Clinic, Chikungunya symptoms usually appear 2 to 7 days after being bitten by an infected mosquito. Common symptoms include: Sudden high fever Headache Fatigue Rash Nausea Red eyes There is currently no specific treatment for the infection, although a vaccine has been approved in the United States. The WHO is urging global action to prevent another widespread outbreak.
Gulf Insider
3 days ago
- Gulf Insider
Vaccination Rates Are Stagnating
Data published last week by the World Health Organization (WHO) and UNICEF confirm that global vaccination coverage has stagnated in recent years. In 2024, 14.3 million children worldwide were classified as 'zero-dose', meaning they had not received a single vaccine. This number has barely changed over the past two years (14.5 million in 2022) and remains higher than the 12.8 million recorded in 2019, before the Covid-19 pandemic disrupted health services. More than half of these unvaccinated children live across around 30 countries currently affected by fragility, conflict or other vulnerabilities. As Statista's Anna Fleck shows in the following chart, the percentage of children who received three doses of the DTP vaccine (which protects against diphtheria, tetanus, and pertussis) stood at 85 percent in 2024. This is slightly below from the 86 percent reached between 2016 and 2019. You will find more infographics at Statista Vaccination rates for other diseases have also stagnated: polio coverage remained at 84 percent in 2024 (down from 86 percent between 2017 and 2019), and tuberculosis vaccination held steady at 88 percent (compared to a peak of 90 percent in 2017 and 2018). As for measles, global coverage improved significantly between 2004 and 2016 but has since slowed. In 2024, the global measles vaccination rate reached 76 percent, up from 71 percent in 2019, yet still well below the 95 percent threshold needed to effectively prevent outbreaks. According to the WHO, 60 countries experienced 'major or disruptive' measles outbreaks in 2024 – nearly double the number recorded in 2022. The primary reason for low vaccination coverage remains limited access to vaccines in certain regions. However, the WHO also highlights the growing threat posed by misinformation about science and vaccines. Also read: US Government Drops Charges Against Doctor Who Issued Fake COVID Vaccination Cards
Gulf Insider
4 days ago
- Gulf Insider
What To Know About Big Pharma, In Charts
Prescription drugs provide relief from pain, fight infection, stabilize moods, reduce inflammation, combat dread diseases, and extend lives. These medications have become a fact of life for many—perhaps most—Americans. On average, half of them took at least one prescription drug in a given month, according to a recent CDC survey. More than 13 percent took five or more. And the rate is growing. In 2020 Americans filled 6.4 billion prescriptions, about 19 per person. By 2023, Americans were consuming more than 210 billion daily doses of medication annually. That's more than 600 pills, shots, drops, IVs, creams, mists, or suppositories for every person in the country. A child born in 2019 in the United States can expect to spend roughly half of his or her life taking prescription medications, according to Jessica Y. Ho, a researcher at Pennsylvania State University. The United States consumes more prescription drugs than any country in the world and spends nearly twice as much for them as all other nations combined. Global pharmaceutical sales were estimated at $1.6 trillion in 2023, according to Statista. That's roughly equal to the gross domestic product of Spain and nearly double that of Switzerland. The ten largest pharmaceutical companies in the United States alone have a combined worth of more than $2.1 trillion. Recent growth in the industry has been driven by the creation of new types of medications including biologics and peptides. These medications can be highly effective but also very expensive. Biologics are drugs derived from living sources rather than chemicals. Medicare paid nearly $66,000 per patient for prescriptions of Humira in 2023. That's a biologic medication to treat rheumatoid arthritis, plaque psoriasis, and other diseases. Development of biologics has more than tripled over the last decade. The Food and Drug Administration (FDA) approved 17 biologics in 2023, up from an average of 4 per year between 1999 and 2013. Americans consumed 72 percent of the top 50 biologic drugs sold in the world in 2022, according to the Department of Health and Human Services. Peptides are drugs that mimic the function of certain substances within the human body. A particular type of peptide called GLP-1 helps regulate blood sugar and appetite. Ozempic, Weygovy, and Trulicity are GLP-1 medications. Medicare Part D alone paid more than $22 billion to provide GLP-1 medications in 2023, an increase of nearly 130 percent in two years. Currently, the GLP-1 market is dominated by Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi, though others are working to develop similar medications. U.S. drug prices were more than double those in other countries as of 2022, and more than 4 times as much for brand-name drugs, according to global consulting firm RAND. Pharmaceutical companies do considerable business with the federal government, deriving $387 billion in payments from Medicare Part D and Medicaid in 2023 alone. Pharmaceutical companies and some 100 allied political action committees spent more than $15 million in campaign contributions during each of the last two presidential elections, and nearly as much during the mid-terms. Those amounts are overshadowed by the pharmaceutical industry's annual lobbying expenditures. The industry spent more than $150 million to influence federal and state legislatures in 2024. Of its more than 700 lobbyists, nearly two thirds were former government employees. The pharmaceutical lobby spent more money over the past quarter century than did electric utilities, oil and gas companies, hospitals and nursing homes—more than the automotive and defense aerospace industries combined. Research Developing new medications is expensive. The average cost of bringing a new drug market can range up to $2 billion, according to data cited by the Congressional Budget Office. Congress aided companies investing in research via the One Big Beautiful Bill Act, which includes a provision for makers of drugs that treat rare diseases. The law widens the definition of a rare disease drug and further delays Medicare price negotiations on drugs that treat them. That allows the makers of those drugs to continue charging Medicare full price for the medications, in order to fund future research. Normally, a drug that has been marketed for at least 9 years and receives $200 million per year in Medicare payments would be eligible for price negotiation.
